The trials and tribulations of structure assisted design of KCa channel activators

Heesung Shim, Brandon M. Brown, Latika Singh, Vikrant Singh, James C. Fettinger, Vladimir Yarov-Yarovoy, Heike Wulff

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Calcium-activated K+ channels constitute attractive targets for the treatment of neurological and cardiovascular diseases. To explain why certain 2-aminobenzothiazole/oxazole-type KCa activators (SKAs) are KCa3.1 selective we previously generated homology models of the C-terminal calmodulin-binding domain (CaM-BD) of KCa3.1 and KCa2.3 in complex with CaM using Rosetta modeling software. We here attempted to employ this atomistic level understanding of KCa activator binding to switch selectivity around and design KCa2.2 selective activators as potential anticonvulsants. In this structure-based drug design approach we used RosettaLigand docking and carefully compared the binding poses of various SKA compounds in the KCa2.2 and KCa3.1 CaM-BD/CaM interface pocket. Based on differences between residues in the KCa2.2 and KCa.3.1 models we virtually designed 168 new SKA compounds. The compounds that were predicted to be both potent and KCa2.2 selective were synthesized, and their activity and selectivity tested by manual or automated electrophysiology. However, we failed to identify any KCa2.2 selective compounds. Based on the full-length KCa3.1 structure it was recently demonstrated that the C-terminal crystal dimer was an artefact and suggested that the “real” binding pocket for the KCa activators is located at the S4-S5 linker. We here confirmed this structural hypothesis through mutagenesis and now offer a new, corrected binding site model for the SKA-type KCa channel activators. SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine) is binding in the interface between the CaM N-lobe and the S4-S5 linker where it makes van der Waals contacts with S181 and L185 in the S45A helix of KCa3.1.

Original languageEnglish (US)
Article number972
JournalFrontiers in Pharmacology
Volume10
Issue numberSEP
DOIs
StatePublished - Jan 1 2019

Fingerprint

Calmodulin
Oxazoles
Calcium-Activated Potassium Channels
Electrophysiology
Drug Design
Mutagenesis
Anticonvulsants
Artifacts
Amines
Cardiovascular Diseases
Software
Binding Sites

Keywords

  • Calcium-activated potassium channels
  • Calmodulin binding domain
  • K activators
  • K2.2
  • K3.1
  • Rosetta
  • SKA-111

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The trials and tribulations of structure assisted design of KCa channel activators. / Shim, Heesung; Brown, Brandon M.; Singh, Latika; Singh, Vikrant; Fettinger, James C.; Yarov-Yarovoy, Vladimir; Wulff, Heike.

In: Frontiers in Pharmacology, Vol. 10, No. SEP, 972, 01.01.2019.

Research output: Contribution to journalArticle

Shim, Heesung ; Brown, Brandon M. ; Singh, Latika ; Singh, Vikrant ; Fettinger, James C. ; Yarov-Yarovoy, Vladimir ; Wulff, Heike. / The trials and tribulations of structure assisted design of KCa channel activators. In: Frontiers in Pharmacology. 2019 ; Vol. 10, No. SEP.
@article{a56d535eca444724856404d11f04093b,
title = "The trials and tribulations of structure assisted design of KCa channel activators",
abstract = "Calcium-activated K+ channels constitute attractive targets for the treatment of neurological and cardiovascular diseases. To explain why certain 2-aminobenzothiazole/oxazole-type KCa activators (SKAs) are KCa3.1 selective we previously generated homology models of the C-terminal calmodulin-binding domain (CaM-BD) of KCa3.1 and KCa2.3 in complex with CaM using Rosetta modeling software. We here attempted to employ this atomistic level understanding of KCa activator binding to switch selectivity around and design KCa2.2 selective activators as potential anticonvulsants. In this structure-based drug design approach we used RosettaLigand docking and carefully compared the binding poses of various SKA compounds in the KCa2.2 and KCa3.1 CaM-BD/CaM interface pocket. Based on differences between residues in the KCa2.2 and KCa.3.1 models we virtually designed 168 new SKA compounds. The compounds that were predicted to be both potent and KCa2.2 selective were synthesized, and their activity and selectivity tested by manual or automated electrophysiology. However, we failed to identify any KCa2.2 selective compounds. Based on the full-length KCa3.1 structure it was recently demonstrated that the C-terminal crystal dimer was an artefact and suggested that the “real” binding pocket for the KCa activators is located at the S4-S5 linker. We here confirmed this structural hypothesis through mutagenesis and now offer a new, corrected binding site model for the SKA-type KCa channel activators. SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine) is binding in the interface between the CaM N-lobe and the S4-S5 linker where it makes van der Waals contacts with S181 and L185 in the S45A helix of KCa3.1.",
keywords = "Calcium-activated potassium channels, Calmodulin binding domain, K activators, K2.2, K3.1, Rosetta, SKA-111",
author = "Heesung Shim and Brown, {Brandon M.} and Latika Singh and Vikrant Singh and Fettinger, {James C.} and Vladimir Yarov-Yarovoy and Heike Wulff",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fphar.2019.00972",
language = "English (US)",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "SEP",

}

TY - JOUR

T1 - The trials and tribulations of structure assisted design of KCa channel activators

AU - Shim, Heesung

AU - Brown, Brandon M.

AU - Singh, Latika

AU - Singh, Vikrant

AU - Fettinger, James C.

AU - Yarov-Yarovoy, Vladimir

AU - Wulff, Heike

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Calcium-activated K+ channels constitute attractive targets for the treatment of neurological and cardiovascular diseases. To explain why certain 2-aminobenzothiazole/oxazole-type KCa activators (SKAs) are KCa3.1 selective we previously generated homology models of the C-terminal calmodulin-binding domain (CaM-BD) of KCa3.1 and KCa2.3 in complex with CaM using Rosetta modeling software. We here attempted to employ this atomistic level understanding of KCa activator binding to switch selectivity around and design KCa2.2 selective activators as potential anticonvulsants. In this structure-based drug design approach we used RosettaLigand docking and carefully compared the binding poses of various SKA compounds in the KCa2.2 and KCa3.1 CaM-BD/CaM interface pocket. Based on differences between residues in the KCa2.2 and KCa.3.1 models we virtually designed 168 new SKA compounds. The compounds that were predicted to be both potent and KCa2.2 selective were synthesized, and their activity and selectivity tested by manual or automated electrophysiology. However, we failed to identify any KCa2.2 selective compounds. Based on the full-length KCa3.1 structure it was recently demonstrated that the C-terminal crystal dimer was an artefact and suggested that the “real” binding pocket for the KCa activators is located at the S4-S5 linker. We here confirmed this structural hypothesis through mutagenesis and now offer a new, corrected binding site model for the SKA-type KCa channel activators. SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine) is binding in the interface between the CaM N-lobe and the S4-S5 linker where it makes van der Waals contacts with S181 and L185 in the S45A helix of KCa3.1.

AB - Calcium-activated K+ channels constitute attractive targets for the treatment of neurological and cardiovascular diseases. To explain why certain 2-aminobenzothiazole/oxazole-type KCa activators (SKAs) are KCa3.1 selective we previously generated homology models of the C-terminal calmodulin-binding domain (CaM-BD) of KCa3.1 and KCa2.3 in complex with CaM using Rosetta modeling software. We here attempted to employ this atomistic level understanding of KCa activator binding to switch selectivity around and design KCa2.2 selective activators as potential anticonvulsants. In this structure-based drug design approach we used RosettaLigand docking and carefully compared the binding poses of various SKA compounds in the KCa2.2 and KCa3.1 CaM-BD/CaM interface pocket. Based on differences between residues in the KCa2.2 and KCa.3.1 models we virtually designed 168 new SKA compounds. The compounds that were predicted to be both potent and KCa2.2 selective were synthesized, and their activity and selectivity tested by manual or automated electrophysiology. However, we failed to identify any KCa2.2 selective compounds. Based on the full-length KCa3.1 structure it was recently demonstrated that the C-terminal crystal dimer was an artefact and suggested that the “real” binding pocket for the KCa activators is located at the S4-S5 linker. We here confirmed this structural hypothesis through mutagenesis and now offer a new, corrected binding site model for the SKA-type KCa channel activators. SKA-111 (5-methylnaphtho[1,2-d]thiazol-2-amine) is binding in the interface between the CaM N-lobe and the S4-S5 linker where it makes van der Waals contacts with S181 and L185 in the S45A helix of KCa3.1.

KW - Calcium-activated potassium channels

KW - Calmodulin binding domain

KW - K activators

KW - K2.2

KW - K3.1

KW - Rosetta

KW - SKA-111

UR - http://www.scopus.com/inward/record.url?scp=85072998303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072998303&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00972

DO - 10.3389/fphar.2019.00972

M3 - Article

AN - SCOPUS:85072998303

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - SEP

M1 - 972

ER -